Orsini Partners with Ascendis to Distribute YORVIPATH® for Rare Disorder Treatment
In a significant move for patient care, Orsini has been chosen by Ascendis Pharma as its specialty pharmacy partner for the distribution of YORVIPATH® (palopegteriparatide) in the United States. This FDA-approved treatment is a parathyroid hormone analog specifically indicated for adults suffering from chronic hypoparathyroidism, a condition that affects approximately 70,000 individuals in the U.S.
Chronic hypoparathyroidism is a rare endocrine disorder that occurs when the body fails to produce adequate parathyroid hormone, leading to low calcium and high phosphorus levels in the blood. Patients may experience a variety of debilitating symptoms such as muscle cramps, bone damage, chronic pain, cataracts, and kidney stones. The introduction of YORVIPATH is expected to provide a much-needed treatment option for those who currently have limited choices.
YORVIPATH is administered in a unique way that ensures patients receive continuous exposure to the active ingredient over a 24-hour period, making it easier to manage the symptoms associated with this rare disorder. The treatment is already approved for use in the European Union, United Kingdom, and European Economic Area, signaling confidence in its effectiveness.
Darin DeCarlo, Chief Growth Officer of Orsini, expressed enthusiasm about the partnership, stating, "We’re thrilled to add YORVIPATH to our growing portfolio of endocrinology therapies. Orsini is built to serve rare disease patients, and we’re excited to partner with Ascendis Pharma to deliver this new treatment option to those suffering from chronic hypoparathyroidism."
Founded in 1987, Orsini has established itself as a leader in providing pharmacy solutions for rare diseases and gene therapies. The company is dedicated to simplifying the process for patients to access advanced medications. Orsini offers comprehensive commercialization solutions, including a nationwide specialty pharmacy, patient services hub, home infusion, nursing network, and third-party logistics. Their dedication to patient care is clear in their motto, No Patient is Left Behind™.
Orsini has earned several industry accreditations, including those from the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and NABP. Additionally, they hold the prestigious Rare Disease Pharmacy Center of Excellence Designation from URAC and have received the Distinction in Rare Diseases from ACHC.
This partnership not only signifies a strong commitment to enhancing treatment options for individuals with chronic hypoparathyroidism but also reinforces Orsini’s focus on serving patients affected by rare diseases. For those interested in learning more about their services, they can reach out to Orsini through their website or customer service line for further information on this groundbreaking treatment and their other services.
Chronic hypoparathyroidism is a rare endocrine disorder that occurs when the body fails to produce adequate parathyroid hormone, leading to low calcium and high phosphorus levels in the blood. Patients may experience a variety of debilitating symptoms such as muscle cramps, bone damage, chronic pain, cataracts, and kidney stones. The introduction of YORVIPATH is expected to provide a much-needed treatment option for those who currently have limited choices.
YORVIPATH is administered in a unique way that ensures patients receive continuous exposure to the active ingredient over a 24-hour period, making it easier to manage the symptoms associated with this rare disorder. The treatment is already approved for use in the European Union, United Kingdom, and European Economic Area, signaling confidence in its effectiveness.
Darin DeCarlo, Chief Growth Officer of Orsini, expressed enthusiasm about the partnership, stating, "We’re thrilled to add YORVIPATH to our growing portfolio of endocrinology therapies. Orsini is built to serve rare disease patients, and we’re excited to partner with Ascendis Pharma to deliver this new treatment option to those suffering from chronic hypoparathyroidism."
Founded in 1987, Orsini has established itself as a leader in providing pharmacy solutions for rare diseases and gene therapies. The company is dedicated to simplifying the process for patients to access advanced medications. Orsini offers comprehensive commercialization solutions, including a nationwide specialty pharmacy, patient services hub, home infusion, nursing network, and third-party logistics. Their dedication to patient care is clear in their motto, No Patient is Left Behind™.
Orsini has earned several industry accreditations, including those from the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC, and NABP. Additionally, they hold the prestigious Rare Disease Pharmacy Center of Excellence Designation from URAC and have received the Distinction in Rare Diseases from ACHC.
This partnership not only signifies a strong commitment to enhancing treatment options for individuals with chronic hypoparathyroidism but also reinforces Orsini’s focus on serving patients affected by rare diseases. For those interested in learning more about their services, they can reach out to Orsini through their website or customer service line for further information on this groundbreaking treatment and their other services.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.